Drug profile · INN
lenvatinib mesylate
LENVIMA
lenvatinib mesylate (LENVIMA) is a vascular endothelial growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — lenvatinib mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 51
- Data quality
- 0.84
Quick answer
lenvatinib mesylate (LENVIMA) is a vascular endothelial growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Primary target: Vascular endothelial growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lenvatinib mesylate?
lenvatinib mesylate (LENVIMA) is a vascular endothelial growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lenvatinib mesylate?
LENVIMA is a marketed brand name for lenvatinib mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lenvatinib mesylate?
lenvatinib mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.